EP1013

• CAT Number: I013184
• CAS Number: 223568-55-6
• Molecular Formula: C₁₈H₂₃FN₂O₆
• Molecular Weight: 382.38
• Purity: ≥95%
• Target: Caspase
• Solubility: DMSO
• IUPAC Name: (3S)-5-fluoro-3-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-4-oxopentanoic acid
• InChI: InChI=1S/C18H23FN2O6/c1-11(2)16(17(25)20-13(8-15(23)24)14(22)9-19)21-18(26)27-10-12-6-4-3-5-7-12/h3-7,11,13,16H,8-10H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t13-,16-/m0/s1
• InChIKey: LYBWGROBJJXCJJ-BBRMVZONSA-N
• SMILES: CC(C)C(C(=O)NC(CC(=O)O)C(=O)CF)NC(=O)OCC1=CC=CC=C1

EP1013 (CAT: I013184) is a broad-spectrum caspase selective inhibitor that has been investigated for its potential applications in the research of type 1 diabetes. Caspases are a family of protease enzymes involved in programmed cell death, and their dysregulation can contribute to various diseases, including diabetes. By inhibiting caspase activity, EP1013 may help regulate cell death processes and potentially offer therapeutic benefits in the context of type 1 diabetes. However, it’s important to note that further research and clinical studies are necessary to fully understand the efficacy and safety of EP1013 in treating this condition.

Reference

[1]. Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008 Jun;57(6):1556-66.